China's drug regulator obtained approval for the adebelimab and the SHR-8068 injections produced by Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiaries Suzhou Shengdiya Biomedical and Shanghai Shengdi Pharmaceutical.
The two injections are indicated for tumor treatments, according to a Saturday filing with the Shanghai bourse.
Shares closed 1% lower in Shanghai on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments